Formoterol Fumarate: Clinical Trials

263 trials of Formoterol Fumarate, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

211 completed, 20 unknown, 12 withdrawn, 11 terminated. 94 Phase 3, 66 Phase 2, 62 Phase 4, 18 Not applicable, 16 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 394Completed 84, Withdrawn 5, Terminated 2, Unknown 2, Not yet recruiting 1
Phase 266Completed 59, Unknown 3, Terminated 2, Active not recruiting 1, Withdrawn 1
Phase 462Completed 36, Unknown 10, Terminated 6, Withdrawn 6, Recruiting 3, Not yet recruiting 1
Not applicable18Completed 12, Unknown 4, Recruiting 1, Terminated 1
Phase 116Completed 14, Active not recruiting 1, Unknown 1

Follow Formoterol Fumarate: new trials by email Literature Review of Formoterol Fumarate trials Research Report on Formoterol Fumarate

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Comparator - Trimbow® - Chronic Obstructive Pulmonary Disease
Phase 3Not yet recruitingEurofarma Laboratorios S.A.12522027-01-302026-10-26
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline) - COPD Exacerbation
Phase 4Not yet recruitingUniversity of Tennessee Graduate School of Medicine2802026-11-122026-10-19
Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)
N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma
Phase 3WithdrawnEurofarma Laboratorios S.A.2026-10-012026-10-23
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation), Foster® 200/6 pMDI (BDP/FF-200/6 µg) - Asthma
Phase 4RecruitingChiesi Farmaceutici S.p.A.6442026-06-282026-07-31
Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil
Administration of investigation drug, Administration of comparator - Moderate Asthma
Phase 3WithdrawnEurofarma Laboratorios S.A.2026-06-012025-12-18
Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma
Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Placebo for CP006 Inhalation Powder - Asthma
Phase 2CompletedShanghai Xin Huanghe Pharmaceutical Co., Ltd.1502025-11-212026-09-08
Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications
Formoterol Fumarate 12 mcg (Foradil Aerolizer), Usual treatment - Thoracic Surgery, Postoperative Pulmonary Complications (PPCs)
Not applicableRecruitingCentre Hospitalier Universitaire, Amiens2662025-07-312026-01-16
Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg - Asthma, Asthma Patients
CompletedChiesi Bulgaria2812025-02-012026-03-19
Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale
RecruitingChiesi Hungary Ltd.8002024-10-242024-11-22
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
Budesonide-Formoterol treatment - Cough-Variant Asthma
Phase 4CompletedAstraZeneca10002024-10-182025-09-18
Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD
budesonide / glycopyrronium / formoterol - Chronic Obstructive Pulmonary Disease (COPD)
CompletedAstraZeneca102024-04-302025-12-22
ANTES B+ Clinical Trial
Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease
Phase 4TerminatedFundacio Privada Mon Clinic Barcelona482024-02-292025-08-14
Budesonide/Formoterol Inhalation Powder in Adults With Asthma
Budesonide and Formoterol Fumarate, Placebo of Budesonide and Formoterol Fumarate - Asthma
Phase 3CompletedShanghai Xin Huanghe Pharmaceutical Co., Ltd.3382024-02-212026-08-27
IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator - COPD
Phase 4WithdrawnAstraZeneca2024-01-192024-02-01
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD
BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA - COPD (Chronic Obstructive Pulmonary Disease)
Phase 3CompletedAstraZeneca2972024-01-112025-08-27
U-LABA/ICS Effects on Exercise Performance, Formoterol
Symbicort, Formoterol, Placebo - Exercise Performance
Not applicableCompletedMorten Hostrup, PhD202024-01-052024-08-13
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ) - COPD (Chronic Obstructive Pulmonary Disease)
Phase 4RecruitingUniversity of Tennessee Graduate School of Medicine722023-12-052026-10-19
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
Vilanterol / Umeclidinium (25/62.5 mcg), Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg - COPD Bronchitis, Pollution Related Respiratory Disorder
Phase 4UnknownNational Institute of Respiratory Diseases, Mexico1282023-11-152024-08-26
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo - Chronic Obstructive Pulmonary Disease
Phase 3CompletedAstraZeneca1712023-10-242026-03-05
Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study
Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device) - COPD
UnknownChiesi SAS5002023-08-012024-03-13

Showing 20 of 263. Sign in to see all of them.

Conditions studied

Pulmonary Disease, Chronic Obstructive (135)  ·  Asthma (102)  ·  Emphysema (18)  ·  Bronchitis, Chronic (14)  ·  Bronchiolitis Obliterans Syndrome (5)  ·  Bronchitis (5)  ·  Motor Activity (4)  ·  Respiratory Aspiration (4)  ·  Cough-Variant Asthma (3)  ·  Dyspnea (3)  ·  Inflammation (3)  ·  Bronchiolitis Obliterans (2)  ·  Disease (2)  ·  Lung Diseases (2)  ·  Lung Diseases, Obstructive (2)

Sponsors

AstraZeneca (56)  ·  Chiesi Farmaceutici S.p.A. (27)  ·  Dey (16)  ·  Sumitomo Pharma America, Inc. (11)  ·  Organon and Co (8)  ·  Novartis Pharmaceuticals (7)  ·  Boehringer Ingelheim (6)  ·  Mundipharma Research Limited (6)  ·  Novartis (6)  ·  Pearl Therapeutics, Inc. (6)  ·  Eurofarma Laboratorios S.A. (5)  ·  GlaxoSmithKline (5)  ·  Orion Corporation, Orion Pharma (4)  ·  SkyePharma AG (4)  ·  University of Tennessee Graduate School of Medicine (4)

Countries

United States (91)  ·  United Kingdom (36)  ·  Germany (33)  ·  Poland (25)  ·  China (20)  ·  Hungary (20)  ·  Canada (18)  ·  Italy (17)  ·  Spain (17)  ·  Bulgaria (16)  ·  Czechia (16)  ·  Romania (16)  ·  France (14)  ·  Russia (14)  ·  Denmark (13)

Top investigators

Esther Garcia, MD (10)  ·  Catherine Bonuccelli (9)  ·  Christer Hultquist, MD (3)  ·  Colin Reisner, M.D. (3)  ·  Arthur F Gelb, MD (2)  ·  Brian Lipworth, MD (2)  ·  Elliot Israel, MD (2)  ·  Emir Festic, MD (2)  ·  Esther Garcia, Ph.D. (2)  ·  Lars-Goran Carlsson, MD (2)  ·  Narongwit Nakwan, M.D. (2)

Results publications

PMID 22329608, PMID 36472162, PMID 21227674, PMID 21397482, PMID 22206353, PMID 22334770, PMID 22560478, PMID 23932460, PMID 24290280, PMID 24953015, PMID 25044280, PMID 25045258, PMID 25187881, PMID 25950858, PMID 26233481, PMID 26343939, PMID 26717511, PMID 28558833, PMID 30077810, PMID 31827323, PMID 32848381, PMID 32943047, PMID 14680096, PMID 15215480, PMID 16164444, PMID 16304262, PMID 17046300, PMID 17296644, PMID 17556723, PMID 17890470, PMID 18042473, PMID 18258423, PMID 18363201, PMID 18655841, PMID 18804362, PMID 18972276, PMID 18977646, PMID 19124372, PMID 19208459, PMID 19229704, PMID 19663129, PMID 19808130, PMID 19897551, PMID 20040610, PMID 20109122, PMID 20170333, PMID 20418370, PMID 20463178, PMID 20522841, PMID 20580216

NIH funding

2009 (4), 2008 (3), 2023 (3), 2014 (2), 2015 (2), 2017 (2), 1UG3HL141722-01A1 (1), 2005 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), KL2TR002346 (1), UL1RR024150 (1), UL1TR002345 (1)